Literature DB >> 8635386

Quality of life as a new end point.

P Kosmidis1.   

Abstract

Quality of life (QOL) is a relatively new clinical end point that is particularly relevant to the typically palliative therapy for non-small cell lung cancer. Patients' assessments of their QOL are shown to differ from their physicians', emphasizing the subjective nature of QOL. A number of relevant instruments and assessment techniques are employed. Results from a study using the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 instrument before and during chemotherapy are presented. Some parameters improved while others did not, preventing a simple interpretation. There are arguments for compiling indexes of QOL while retaining measures for individual parameters and a desire for the consistent international use of an instrument such as the EORTC questionnaire.

Entities:  

Mesh:

Year:  1996        PMID: 8635386     DOI: 10.1378/chest.109.5_supplement.110s

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  6 in total

1.  Strength and endurance training in the treatment of lung cancer patients in stages IIIA/IIIB/IV.

Authors:  C C Henke; J Cabri; L Fricke; W Pankow; G Kandilakis; P C Feyer; M de Wit
Journal:  Support Care Cancer       Date:  2013-09-01       Impact factor: 3.603

2.  Monitoring changes in quality of life in patients with lung cancer by using specialised questionnaires: implications for clinical practice.

Authors:  Hellie Lithoxopoulou; Konstantinos Zarogoulidis; Sevasti Bostantzopoulou; Ellada Eleftheriadou; Paul Zarogoulidis; Haidong Huang; Konstantinos Porpodis; Ioannis Kioumis; Theodora Tsiouda; Lonny Yarmus; Theodore Kontakiotis
Journal:  Support Care Cancer       Date:  2014-03-22       Impact factor: 3.603

3.  Health-related quality of life in breast cancer patients in Asia: A meta-analysis and systematic review.

Authors:  Xinyu Chen; Chenxi Wu; Dingxi Bai; Jing Gao; Chaoming Hou; Tingting Chen; Lulu Zhang; Huan Luo
Journal:  Front Oncol       Date:  2022-09-28       Impact factor: 5.738

Review 4.  Cardiopulmonary rehabilitation after treatment for lung cancer.

Authors:  Jeanette Nazarian
Journal:  Curr Treat Options Oncol       Date:  2004-02

5.  In Metastatic Non-small cell Lung Cancer Platinum-Based Treated Patients, Herbal Treatment Improves the Quality of Life. A Prospective Randomized Controlled Clinical Trial.

Authors:  Huiru Guo; Jia X Liu; Hegen Li; Jan P A Baak
Journal:  Front Pharmacol       Date:  2017-07-17       Impact factor: 5.810

6.  Hematological Malignancy Specific Patient-Reported Outcome Measure (HM-PRO): Construct Validity Study.

Authors:  Pushpendra Goswami; Esther N Oliva; Tatyana Ionova; Roger Else; Jonathan Kell; Adele K Fielding; Daniel M Jennings; Marina Karakantza; Saad Al-Ismail; Graham P Collins; Stewart McConnell; Catherine Langton; Magda J Al-Obaidi; Metod Oblak; Sam Salek
Journal:  Front Pharmacol       Date:  2020-09-08       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.